HK1204261A1 - Immunogenic wt-1 peptides and methods of use thereof wt-1 - Google Patents
Immunogenic wt-1 peptides and methods of use thereof wt-1Info
- Publication number
- HK1204261A1 HK1204261A1 HK15104710.4A HK15104710A HK1204261A1 HK 1204261 A1 HK1204261 A1 HK 1204261A1 HK 15104710 A HK15104710 A HK 15104710A HK 1204261 A1 HK1204261 A1 HK 1204261A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- immunogenic
- peptides
- methods
- Prior art date
Links
- 230000002163 immunogen Effects 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001152—Transcription factors, e.g. SOX or c-MYC
- A61K39/001153—Wilms tumor 1 [WT1]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464452—Transcription factors, e.g. SOX or c-MYC
- A61K39/464453—Wilms tumor 1 [WT1]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
- A61K2039/55594—Adjuvants of undefined constitution from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261586177P | 2012-01-13 | 2012-01-13 | |
US201261647207P | 2012-05-15 | 2012-05-15 | |
PCT/US2013/021448 WO2013106834A2 (fr) | 2012-01-13 | 2013-01-14 | Peptides wt-1 immunogènes et leurs procédés d'utilisation |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1204261A1 true HK1204261A1 (en) | 2015-11-13 |
Family
ID=48782099
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15104710.4A HK1204261A1 (en) | 2012-01-13 | 2015-05-18 | Immunogenic wt-1 peptides and methods of use thereof wt-1 |
Country Status (8)
Country | Link |
---|---|
US (3) | US20150104413A1 (fr) |
EP (2) | EP2802347B1 (fr) |
JP (2) | JP6282598B2 (fr) |
CN (2) | CN104684577B (fr) |
AU (2) | AU2013207669C1 (fr) |
CA (1) | CA2861206C (fr) |
HK (1) | HK1204261A1 (fr) |
WO (1) | WO2013106834A2 (fr) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6282598B2 (ja) | 2012-01-13 | 2018-02-21 | メモリアル スローン ケタリング キャンサー センター | 免疫原性wt1ペプチド及びその使用方法 |
EP3640375A3 (fr) | 2012-12-11 | 2020-07-29 | Albert Einstein College of Medicine | Procédés pour identification de récepteur/ligand à rendement élevé |
WO2015164826A2 (fr) * | 2014-04-24 | 2015-10-29 | Rhode Island Hospital | Induction par l'aspartate-ss-hydroxylase d'une réponse des cellules t spécifique des épitopes dans les tumeurs |
CN108350411B (zh) * | 2015-06-25 | 2021-06-22 | 白川利朗 | 口服肿瘤疫苗 |
MX2018002816A (es) * | 2015-09-10 | 2018-06-08 | Memorial Sloan Kettering Cancer Center | Metodos de tratamiento de mieloma multiple y leucemia de celulas plasmaticas mediante terapia de celulas t. |
EP3362929B1 (fr) * | 2015-10-12 | 2020-08-12 | Nantomics, LLC | Néoépitopes viraux et utilisations de ces derniers |
AU2016356708B2 (en) | 2015-11-20 | 2022-02-03 | Memorial Sloan Kettering Cancer Center | Methods and compositions for treating cancer |
IL262606B2 (en) | 2016-05-18 | 2023-04-01 | Albert Einstein College Medicine Inc | pd-l1 variant polypeptides, T-cell modulatory multimeric polypeptides, and methods of using them |
JP7071288B2 (ja) | 2016-05-18 | 2022-05-18 | キュー バイオファーマ, インコーポレイテッド | T細胞調節多量体ポリペプチド及びその使用方法 |
CN110506107A (zh) | 2016-11-30 | 2019-11-26 | 阿德瓦希斯公司 | 靶向复发性癌症突变的免疫原性组合物及其使用方法 |
SI3558339T1 (sl) | 2016-12-22 | 2024-05-31 | Cue Biopharma, Inc. | Celico T modulirajoči multimerni polipeptidi in postopki njihove uporabe |
EP4032911A1 (fr) | 2017-01-06 | 2022-07-27 | Eutilex Co., Ltd. | Anticorps anti 4-1bb anti-humains et leurs utilisations |
WO2018129474A1 (fr) | 2017-01-09 | 2018-07-12 | Cue Biopharma, Inc. | Polypeptides multimères modulateurs de lymphocytes t et leurs procédés d'utilisation |
IL309479A (en) | 2017-03-15 | 2024-02-01 | Cue Biopharma Inc | Methods for modulating an immune response |
CN111315768A (zh) | 2017-09-07 | 2020-06-19 | 库尔生物制药有限公司 | 具有缀合位点的t细胞调节性多聚体多肽及其使用方法 |
SG11202004107YA (en) * | 2017-11-08 | 2020-06-29 | Advaxis Inc | Immunogenic heteroclitic peptides from cancer-associated proteins and methods of use thereof |
EP3737689A4 (fr) | 2018-01-09 | 2021-12-01 | Cue Biopharma, Inc. | Polypeptides multimères modulateurs de lymphocytes t et leurs procédés d'utilisation |
EP3801597A4 (fr) * | 2018-05-25 | 2022-05-04 | The Wistar Institute | Néo-antigènes spécifiques d'une tumeur et leurs méthodes d'utilisation |
WO2020132366A2 (fr) * | 2018-12-19 | 2020-06-25 | Cue Biopharma, Inc. | Polypeptides multimères modulateurs des lymphocytes t ayant des sites de conjugaison et procédés d'utilisation associés |
CN110423723A (zh) * | 2019-07-18 | 2019-11-08 | 南方医科大学南方医院 | 一种外周血b细胞系的构建方法及其应用 |
KR20220129567A (ko) | 2019-12-31 | 2022-09-23 | 엘릭서젠 쎄라퓨틱스, 인크. | 핵산 및 단백질의 세포 및 조직으로의 온도-기반 일시적 전달 |
WO2021231376A2 (fr) | 2020-05-12 | 2021-11-18 | Cue Biopharma, Inc. | Polypeptides multimères modulateurs de lymphocytes t et leurs méthodes d'utilisation |
EP4211149A1 (fr) | 2020-09-09 | 2023-07-19 | Cue Biopharma, Inc. | Polypeptides multimères modulateurs des lymphocytes t du cmh de classe ii pour le traitement du diabète sucré de type 1 (dt1) et leurs procédés d'utilisation |
Family Cites Families (118)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA8748A (fr) | 1878-05-04 | George W. Ainsworth | Perfectionnements aux sechoirs a linge | |
CA23766A (fr) | 1886-04-06 | Albert M. Todd | Procede de traitement des huiles volatiles pour en extraire le cristallin de la partie liquide | |
CA59350A (fr) | 1898-02-26 | 1898-03-19 | Thomas Henry Simmonds | Frein pour velocipedes, tricycles, etc. |
US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
US5837249A (en) | 1985-04-19 | 1998-11-17 | The Wistar Institute | Method for generating an immunogenic T cell response protective against a virus |
US5726288A (en) * | 1989-11-13 | 1998-03-10 | Massachusetts Institute Of Technology | Localization and characterization of the Wilms' tumor gene |
US5229115A (en) | 1990-07-26 | 1993-07-20 | Immunex Corporation | Adoptive immunotherapy with interleukin-7 |
CA2103577A1 (fr) | 1991-02-07 | 1992-08-08 | Michael Kahn | Structures a conformation restreinte mimetiques de tours beta et de saillies beta et peptides en contenant |
EP0692973A1 (fr) | 1993-03-15 | 1996-01-24 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Cellules dendritiques enrobees de peptide utilisees en tant qu'immunogenes |
WO1995029240A1 (fr) | 1994-04-22 | 1995-11-02 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Isolement et caracterisation d'un nouveau virus simien t-lymphotrope et utilisation de ce virus ou de ses constituants dans des methodes de diagnostic et dans des vaccins |
US5622835A (en) | 1994-04-28 | 1997-04-22 | The Wistar Institute Of Anatomy & Biology | WT1 monoclonal antibodies |
US5643786A (en) | 1995-01-27 | 1997-07-01 | The United States Of America As Represented By The Department Of Health And Human Services | Method for isolating dendritic cells |
US6156316A (en) | 1995-05-08 | 2000-12-05 | Sloan-Kettering Institute For Cancer Research | Oncogene fusion protein peptide vaccines |
JPH11171896A (ja) | 1995-09-19 | 1999-06-29 | Kirin Brewery Co Ltd | 新規ペプチド化合物およびその医薬組成物 |
US5981217A (en) | 1995-12-11 | 1999-11-09 | Mayo Foundation For Medical Education And Research | DNA encoding TGF-β inducible early factor-1 (TIEF-1), a gene expressed by osteoblasts |
AU1394497A (en) | 1996-01-17 | 1997-08-11 | Imperial College Innovations Limited | Immunotherapy using cytotoxic t lymphocytes (ctl) |
US5853719A (en) | 1996-04-30 | 1998-12-29 | Duke University | Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA |
US6207375B1 (en) | 1996-12-11 | 2001-03-27 | Mayo Foundation For Medical Educational & Research | TGF-β inducible early factor-1 (TIEF-1) and a method to detect breast cancer |
ID27813A (id) | 1998-01-28 | 2001-04-26 | Corixa Corp | Senyawa-senyawa untuk terapi dan diagnosa kanker paru-paru dan metoda untuk penggunaannya |
CN1560078B (zh) | 1998-07-31 | 2011-06-22 | 株式会社国际癌症免疫研究所 | 基于癌抑制基因wt1的产物的癌抗原 |
US7115272B1 (en) | 1998-09-30 | 2006-10-03 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
US20030235557A1 (en) | 1998-09-30 | 2003-12-25 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
US7063854B1 (en) * | 1998-09-30 | 2006-06-20 | Corixa Corporation | Composition and methods for WTI specific immunotherapy |
US20120301492A1 (en) | 1998-09-30 | 2012-11-29 | Corixa Corporation | Compositions and methods for wt1 specific immunotherapy |
US7655249B2 (en) | 1998-09-30 | 2010-02-02 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
US7901693B2 (en) | 1998-09-30 | 2011-03-08 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
US7329410B1 (en) | 1998-09-30 | 2008-02-12 | Corixa Corporation | Compositions and method for WT1 specific immunotherapy |
US7144581B2 (en) | 2000-10-09 | 2006-12-05 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
US20030072767A1 (en) | 1998-09-30 | 2003-04-17 | Alexander Gaiger | Compositions and methods for WT1 specific immunotherapy |
GB9823897D0 (en) | 1998-11-02 | 1998-12-30 | Imp College Innovations Ltd | Immunotherapeutic methods and molecules |
WO2000037491A2 (fr) | 1998-12-22 | 2000-06-29 | Genset | Adn complementaires codant pour des proteines secretees avec des peptides signaux |
AU3395900A (en) | 1999-03-12 | 2000-10-04 | Human Genome Sciences, Inc. | Human lung cancer associated gene sequences and polypeptides |
CA2367692A1 (fr) | 1999-03-15 | 2000-09-21 | Introgen Therapeutics, Inc. | Cellules dendritiques transduites avec un gene du soi de type sauvage suscitant des reponses immunitaires antitumorales puissantes |
US6593299B1 (en) * | 1999-04-21 | 2003-07-15 | University Of Florida Research Foundation, Inc. | Compositions and methods for controlling pests |
WO2001025273A2 (fr) | 1999-10-04 | 2001-04-12 | Corixa Corporation | Compositions et methodes se rapportant a une immunotherapie specifique a wt1 |
CA2401070A1 (fr) * | 2000-02-22 | 2001-08-30 | Corixa Corporation | Compositions et methodes destinees au diagnostic et a la therapie du mesotheliome malin |
US20030082194A1 (en) | 2000-02-22 | 2003-05-01 | Alexander Gaiger | Compositions and methods for diagnosis and therapy of malignant mesothelioma |
US20040002068A1 (en) | 2000-03-01 | 2004-01-01 | Corixa Corporation | Compositions and methods for the detection, diagnosis and therapy of hematological malignancies |
US6861234B1 (en) | 2000-04-28 | 2005-03-01 | Mannkind Corporation | Method of epitope discovery |
EP1209226A3 (fr) | 2000-11-07 | 2002-06-05 | GSF-Forschungszentrum für Umwelt und Gesundheit GmbH | Maturation de cellules dendritiques grâce à la protéine de choc thermique 70 (hsp70) recombinante |
CA2440303C (fr) | 2001-03-22 | 2013-03-19 | Haruo Sugiyama | Peptide modifie wt1 |
US8771702B2 (en) | 2001-03-26 | 2014-07-08 | The Trustees Of The University Of Pennsylvania | Non-hemolytic LLO fusion proteins and methods of utilizing same |
WO2003002142A1 (fr) | 2001-06-29 | 2003-01-09 | Chugai Seiyaku Kabushiki Kaisha | Vaccin anticarcinogene contenant un antigene tumoral base sur un produit de gene wt1 suppresseur de tumeur et des liposomes cationiques |
US7553494B2 (en) | 2001-08-24 | 2009-06-30 | Corixa Corporation | WT1 fusion proteins |
JPWO2003028758A1 (ja) | 2001-09-28 | 2005-01-13 | 治夫 杉山 | 抗原特異的t細胞の誘導方法 |
US8735357B2 (en) | 2001-09-28 | 2014-05-27 | International Institute Of Cancer Immunology, Inc. | Method of inducing antigen-specific T cells |
US20030072761A1 (en) | 2001-10-16 | 2003-04-17 | Lebowitz Jonathan | Methods and compositions for targeting proteins across the blood brain barrier |
US20030175272A1 (en) | 2002-03-07 | 2003-09-18 | Medcell Biologics, Inc. | Re-activated T-cells for adoptive immunotherapy |
ATE466084T1 (de) | 2002-06-12 | 2010-05-15 | Int Inst Cancer Immunology Inc | Hla-a24-restringiertes krebsantigenpeptid |
MXPA05008340A (es) | 2003-02-06 | 2006-03-13 | Cerus Corp | Microbios de vida libre modificados, composiciones de vacuna y metodos de uso de los mismos. |
US20050008618A1 (en) | 2003-02-27 | 2005-01-13 | Howard Kaufman | Composition for delivering an agent to a target cell and uses thereof |
ES2527946T3 (es) * | 2003-03-05 | 2015-02-02 | Dendreon Corporation | Composiciones y métodos que emplean polipéptidos de marco de lectura alternativa para el tratamiento de cáncer y enfermedades infecciosas |
ES2478446T3 (es) | 2003-06-27 | 2014-07-22 | International Institute Of Cancer Immunology, Inc. | Método de selección de pacientes candidatos para la vacuna contra WT1 |
US20050147621A1 (en) | 2003-10-10 | 2005-07-07 | Higgins Darren E. | Use of bacterial 5' untranslated regions for nucleic acid expression |
KR101213015B1 (ko) | 2003-11-05 | 2012-12-26 | 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 | Wt1 로부터 유도된 hla-dr 결합성 항원 펩티드 |
US7488718B2 (en) * | 2003-12-01 | 2009-02-10 | Sloan Kettering Institue For Cancer Research | Synthetic HLA binding peptide analogues and uses thereof |
ES2484340T3 (es) | 2003-12-05 | 2014-08-11 | Multimmune Gmbh | Anticuerpos anti hsp70 terapéuticos y diagnósticos |
EP1550458A1 (fr) | 2003-12-23 | 2005-07-06 | Vectron Therapeutics AG | Adjuvants liposomals synergiques |
EP1720565A1 (fr) | 2004-03-04 | 2006-11-15 | Corixa Corporation | Formulations d'immunostimulants en microspheres et de polypeptide wt1 en co-encapsulation, et procedes correspondants |
US20050214268A1 (en) | 2004-03-25 | 2005-09-29 | Cavanagh William A Iii | Methods for treating tumors and cancerous tissues |
US20050221481A1 (en) | 2004-03-30 | 2005-10-06 | Istituto Superiore Di Sanita' | Amplification of T cells from human cord blood in serum-deprived culture stimulated with stem cell factor, interleukin-7 and interleukin-2 |
SI1731605T1 (sl) | 2004-03-31 | 2010-07-30 | Internat Inst Of Cancer Immunolog Inc | Peptidi antigena karcinoma izvedeni iz WT1 |
US9629927B2 (en) | 2005-07-29 | 2017-04-25 | Sloan-Kettering Institute For Cancer Research | Single wall nanotube constructs and uses thereof |
AU2006304573B2 (en) | 2005-10-17 | 2012-05-24 | Sloan Kettering Institute For Cancer Research | WT1 HLA class II-binding peptides and compositions and methods comprising same |
CN101336249A (zh) * | 2005-11-30 | 2008-12-31 | 株式会社癌免疫研究所 | 新型肽化合物 |
PL1988163T3 (pl) | 2006-02-22 | 2012-11-30 | Int Inst Cancer Immunology Inc | Ograniczony do hla-a*3303 peptyd wt1 i zawierająca go kompozycja farmaceutyczna |
JP5231997B2 (ja) | 2006-03-29 | 2013-07-10 | 株式会社癌免疫研究所 | WT117AA(−)アイソフォーム特異的siRNAおよびその利用 |
WO2007120603A2 (fr) | 2006-04-10 | 2007-10-25 | Sloan Kettering Institute For Cancer Research | Peptides bcr-abl immunogènes et leurs méthodes d'utilisation |
EP3117836A1 (fr) | 2006-04-10 | 2017-01-18 | Sloan Kettering Institute For Cancer Research | Peptides wt-1 immunogènes et leurs utilisations |
NZ619576A (en) | 2006-12-27 | 2014-07-25 | Harvard College | Compositions and methods for the treatment of infections and tumors |
CA2886619A1 (fr) | 2006-12-28 | 2008-07-10 | International Institute Of Cancer Immunology, Inc. | Peptide wt1 a restriction hla-a<sp>*</sp>1101 et composition pharmaceutique le contenant |
KR101323540B1 (ko) | 2007-02-07 | 2013-10-29 | 사이단호진한다이비세이부쯔뵤우겐큐우카이 | 암의 치료제 |
CN104774910B (zh) | 2007-02-27 | 2018-04-10 | 株式会社癌免疫研究所 | 活化辅助t细胞的方法以及用于该方法的组合物 |
AR066676A1 (es) | 2007-05-24 | 2009-09-02 | Glaxosmithkline Biolog Sa | Composicion antigenica liofilizada que contiene un agonista del receptor tipo toll |
KR100995340B1 (ko) | 2007-11-19 | 2010-11-19 | 재단법인서울대학교산학협력재단 | 자연 살해 t 세포의 리간드와 항원을 적재한 단핵구 또는미분화 골수성 세포를 포함하는 백신 |
TWI455721B (zh) | 2007-12-05 | 2014-10-11 | Int Inst Cancer Immunology Inc | 癌疫苗組合物 |
KR100900837B1 (ko) | 2007-12-07 | 2009-06-04 | (주)두비엘 | 리포펩타이드와 폴리(i:c)를 아쥬반트로 포함하는 강력한백신 조성물 |
WO2009143085A1 (fr) | 2008-05-19 | 2009-11-26 | Anza Therapeutics, Inc. | Compositions comportant un mutant prfa de listeria, et leurs procédés d'utilisation |
EP2337795A2 (fr) * | 2008-10-01 | 2011-06-29 | Dako Denmark A/S | Multimères de mhc dans des vaccins et la surveillance immunitaire contre le cancer |
AR076349A1 (es) | 2009-04-23 | 2011-06-01 | Int Inst Cancer Immunology Inc | Peptido auxiliar del antigeno del cancer |
WO2011059835A2 (fr) | 2009-11-11 | 2011-05-19 | Quest Diagnostics Investments Incorporated | Mutations wt1 pour le pronostic de troubles myéloprolifératifs |
US20110136141A1 (en) | 2009-12-03 | 2011-06-09 | Abbott Laboratories | Peptide reagents and method for inhibiting autoantibody antigen binding |
WO2011100754A1 (fr) | 2010-02-15 | 2011-08-18 | The Trustees Of The University Of Pennsylvania | Vaccins à base d'une listeria vivante à titre de thérapie pour le système nerveux central |
JP2013536240A (ja) | 2010-08-24 | 2013-09-19 | ユニヴァーシティ オヴ ピッツバーグ オヴ ザ コモンウェルス システム オヴ ハイアー エデュケーション | インターロイキン−13受容体α2ペプチド脳がんワクチン |
ES2849187T3 (es) | 2010-10-05 | 2021-08-16 | Int Inst Cancer Immunology Inc | Método para activar células T auxiliares |
PE20140405A1 (es) | 2011-03-11 | 2014-03-22 | Gilead Calistoga Llc | Terapias combinadas para malignidades hematologicas |
US9803246B2 (en) | 2011-06-28 | 2017-10-31 | International Institute Of Cancer Immunology, Inc. | Receptor gene for peptide cancer antigen-specific T cell |
US9783821B2 (en) | 2011-07-29 | 2017-10-10 | Riken | Cell for use in immunotherapy which contains modified nucleic acid construct encoding wilms tumor gene product or fragment thereof, method for producing said cell, and said nucleic acid construct |
US9539299B2 (en) | 2011-10-27 | 2017-01-10 | International Institute Of Cancer Immunology, Inc. | Combination therapy with WT1 peptide vaccine and temozolomide |
CN104136609B (zh) | 2011-12-14 | 2016-12-07 | 国立大学法人高知大学 | 辅助性t细胞诱导多肽的修饰 |
JP6282598B2 (ja) | 2012-01-13 | 2018-02-21 | メモリアル スローン ケタリング キャンサー センター | 免疫原性wt1ペプチド及びその使用方法 |
US9303079B2 (en) | 2012-04-02 | 2016-04-05 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
JP6251734B2 (ja) | 2012-05-03 | 2017-12-27 | フレッド ハッチンソン キャンサー リサーチ センター | 親和性増強型t細胞受容体およびその作製方法 |
ES2655031T3 (es) | 2012-07-02 | 2018-02-16 | Sumitomo Dainippon Pharma Co., Ltd. | Preparación transdérmica de péptido antigénico del cáncer |
CN109106945B (zh) | 2012-10-23 | 2023-04-18 | 优比维克有限责任公司 | 用于治疗疾病的同种异体自噬体富集组合物 |
JP6530192B2 (ja) | 2012-12-17 | 2019-06-12 | 大塚製薬株式会社 | ヘルパーt細胞の活性化方法 |
CN104968782B (zh) | 2012-12-26 | 2019-09-06 | 生物科莫公司 | 利用人副流感2型病毒载体的疫苗 |
CN116789792A (zh) | 2013-01-15 | 2023-09-22 | 纪念斯隆凯特林癌症中心 | 免疫原性wt-1肽和其使用方法 |
EP2762160A1 (fr) | 2013-02-05 | 2014-08-06 | Nitto Denko Corporation | Composition de vaccin contre le cancer peptidique WT1 pour administration mucosale |
RU2697443C2 (ru) | 2013-02-05 | 2019-08-14 | Нитто Денко Корпорейшн | Препарат противораковой вакцины, содержащий пептид wt1, в форме ленты трансдермального введения |
RU2687144C2 (ru) | 2013-02-05 | 2019-05-07 | Нитто Денко Корпорейшн | Композиция противораковой вакцины, содержащей пептид wt1, для трансдермального введения |
US10071051B2 (en) | 2013-02-05 | 2018-09-11 | Nitto Denko Corporation | WT1 peptide cancer vaccine composition for transdermal administration |
CA2898474A1 (fr) | 2013-02-14 | 2014-08-21 | Immunocellular Therapeutics, Ltd. | Vaccins contre le cancer et methodes de vaccination |
JP6294868B2 (ja) | 2013-03-12 | 2018-03-14 | 大日本住友製薬株式会社 | 液体水性組成物 |
CN114225019A (zh) | 2013-03-15 | 2022-03-25 | 宾夕法尼亚大学理事会 | 癌疫苗及使用其的治疗方法 |
DK2982681T3 (en) | 2013-03-29 | 2018-12-10 | Sumitomo Dainippon Pharma Co Ltd | WT1 ANTIGENPEPTIDKONJUGATVACCINE |
EP2988762B1 (fr) | 2013-04-25 | 2018-06-06 | Vaximm AG | Vecteurs à base de salmonelle pour l'immunothérapie du cancer ciblants le gène de la tumeur de wilms wt1 |
ES2954899T3 (es) | 2013-05-13 | 2023-11-27 | Int Inst Cancer Immunology Inc | Procedimiento para predecir el efecto clínico de una inmunoterapia |
WO2015002134A1 (fr) | 2013-07-02 | 2015-01-08 | 公益財団法人がん研究会 | Vaccin induisant une immunité cellulaire |
MX2016006625A (es) | 2013-11-22 | 2016-12-02 | Univ Illinois | Receptores de células t humanas con alta afinidad modificados por medio de manipulación genética. |
LT3082850T (lt) | 2013-12-18 | 2019-11-11 | Vaximm Gmbh | Į msln nukreipta dnr vakcina vėžio imunoterapijai |
KR20220062143A (ko) | 2014-01-06 | 2022-05-13 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | Pd1 및 pdl1 항체 및 백신 조합 및 면역요법을 위한 이들의 사용 |
EA035259B1 (ru) | 2014-02-14 | 2020-05-21 | Иммьюн Дизайн Корп. | Иммунотерапия рака с применением комбинации местной и системной иммунной стимуляции |
EP3112378B1 (fr) | 2014-02-26 | 2020-06-24 | Tella, Inc. | Polypeptide antigénique wt1, et agent antitumoral contenant ledit polypeptide |
US10023841B2 (en) | 2014-05-23 | 2018-07-17 | Baylor Research Institute | Methods and compositions for treating breast cancer with dendritic cell vaccines |
CA2970236A1 (fr) | 2014-12-11 | 2016-06-16 | International Institute Of Cancer Immunology, Inc. | Compositions comprenant un peptide de wt1 pour l'immunotherapie d'une maladie angiogenique |
CN108350411B (zh) | 2015-06-25 | 2021-06-22 | 白川利朗 | 口服肿瘤疫苗 |
US20190054112A1 (en) | 2015-09-18 | 2019-02-21 | Moderna Therapeutics, Inc. | Polynucleotide formulations for use in the treatment of renal diseases |
-
2013
- 2013-01-14 JP JP2014552368A patent/JP6282598B2/ja active Active
- 2013-01-14 AU AU2013207669A patent/AU2013207669C1/en active Active
- 2013-01-14 EP EP13736176.2A patent/EP2802347B1/fr active Active
- 2013-01-14 CN CN201380014022.7A patent/CN104684577B/zh active Active
- 2013-01-14 CN CN201810342393.2A patent/CN108676069A/zh active Pending
- 2013-01-14 WO PCT/US2013/021448 patent/WO2013106834A2/fr active Application Filing
- 2013-01-14 CA CA2861206A patent/CA2861206C/fr active Active
- 2013-01-14 EP EP18215878.2A patent/EP3520810A3/fr active Pending
- 2013-01-14 US US14/372,174 patent/US20150104413A1/en not_active Abandoned
-
2015
- 2015-05-18 HK HK15104710.4A patent/HK1204261A1/xx unknown
-
2017
- 2017-05-30 US US15/608,964 patent/US10100087B2/en active Active
-
2018
- 2018-01-24 JP JP2018009786A patent/JP6995645B2/ja active Active
- 2018-02-20 AU AU2018201210A patent/AU2018201210B2/en active Active
- 2018-09-07 US US16/125,213 patent/US10815274B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP6282598B2 (ja) | 2018-02-21 |
AU2018201210A1 (en) | 2018-03-08 |
JP2018104438A (ja) | 2018-07-05 |
US10815274B2 (en) | 2020-10-27 |
EP3520810A3 (fr) | 2019-11-06 |
JP2015512866A (ja) | 2015-04-30 |
JP6995645B2 (ja) | 2022-01-14 |
US20170334951A1 (en) | 2017-11-23 |
EP2802347A4 (fr) | 2016-06-01 |
CN108676069A (zh) | 2018-10-19 |
AU2013207669A1 (en) | 2014-08-07 |
AU2018201210B2 (en) | 2020-04-09 |
EP3520810A2 (fr) | 2019-08-07 |
CA2861206A1 (fr) | 2013-07-18 |
EP2802347B1 (fr) | 2019-01-09 |
CN104684577B (zh) | 2018-05-08 |
AU2013207669B9 (en) | 2017-12-14 |
EP2802347A2 (fr) | 2014-11-19 |
US20150104413A1 (en) | 2015-04-16 |
AU2013207669C1 (en) | 2018-05-31 |
WO2013106834A3 (fr) | 2015-01-22 |
US20190092813A1 (en) | 2019-03-28 |
CA2861206C (fr) | 2021-07-06 |
AU2013207669B2 (en) | 2017-11-23 |
CN104684577A (zh) | 2015-06-03 |
US10100087B2 (en) | 2018-10-16 |
WO2013106834A2 (fr) | 2013-07-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1204261A1 (en) | Immunogenic wt-1 peptides and methods of use thereof wt-1 | |
SI2945647T1 (sl) | Imunogeni peptidi WT-1 in postopki za uporabo le-teh | |
EP2912178A4 (fr) | Super-activateurs et procédés d'utilisation de ceux-ci | |
HK1208439A1 (en) | 5-azaindazole compounds and methods of use 5- | |
HK1199892A1 (en) | Modified mini-hepcidin peptides and methods of using thereof | |
ZA201501858B (en) | Anti-mcam antibodies and associated methods of use | |
PT2925782T (pt) | Anticorpos anti-cd47 e métodos de utilização destes | |
ZA201405858B (en) | Recombinant microorganisms and methods of use thereof | |
EP2895083A4 (fr) | Ligateur et procédé d'utilisation | |
EP2870170A4 (fr) | Nouveaux peptides et leur utilisation | |
IL238227A0 (en) | Antibodies against c16orf54 and uses thereof | |
HK1206037A1 (en) | Human antibodies to gfr3 and methods of use thereof gfr3 | |
HK1197187A1 (en) | Anti-lrp5 antibodies and methods of use lrp5 | |
EP2782589A4 (fr) | Peptides antimicrobiens et procédés d'utilisation de ces derniers | |
HK1225645A1 (zh) | Pcv2b趨異株疫苗組合物以及使用方法 | |
EP2863858A4 (fr) | Systèmes de soutien pour patient et leurs procédés d'utilisation | |
EP2806811A4 (fr) | Construction vertébrale | |
HK1203161A1 (en) | Peptides and methods of using same | |
EP2897639A4 (fr) | Compositions de vaccins perfectionnées et méthodes d'utilisation | |
EP2938632A4 (fr) | Anticorps anti-granulysine et leurs procédés d'utilisation | |
EP2852397A4 (fr) | Variants d'huwentoxine iv et procédés d'utilisation | |
HK1209432A1 (en) | Anti-jagged antibodies and methods of use | |
SG11201504805PA (en) | Porcine parvovirus 5a, methods of use and vaccine | |
EP2897680A4 (fr) | Dispositifs de gonflage et leurs procédés d'utilisation | |
EP2925341A4 (fr) | Composés peptidiques et leurs procédés de production et d'utilisation |